NASDAQ$ASTH

Astrana Health Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Apollo Medical Holdings reported strong financial results driven by revenue growth and strategic transactions.

ApolloMed reported a 40% increase in revenue to $317.0 million, but net income attributable to AMEH decreased to $26.0 million. The company closed acquisitions of All American Medical Group and Valley Oaks Medical Group in October 2022, and entered into an agreement to acquire For Your Benefit. The company is raising annual guidance for revenue, net income and EBITDA, and reiterating guidance for Adjusted EBITDA.

  • Revenue increased by 40% to $317.0 million compared to Q3 2021.
  • Net income attributable to AMEH was $26.0 million, compared to $34.3 million in the prior year.
  • Diluted EPS was $0.56, compared to $0.74 in the prior year.
  • Adjusted EBITDA was $57.1 million, compared to $62.9 million in the prior year.

Headline financials

Total Revenue

$317M

Previous: $227M+39.6%
EPS (adj)

$0.52

Previous: $0.78-33.3%
Capital Expenditures

-$22.1M

Previous: -$16.4M-34.3%
Free Cash Flow

$3.93M

Previous: $17.9M-78.0%
Net Income

$26M

Previous: $34.3M-24.2%
Operating Income

$50.1M

Previous: $53.2M-5.8%
Gross Profit

-$245M

Previous: -$152M-61.5%
Cash & Equivalents

$184M

Previous: $205M-10.1%
Total Assets

$943M

Previous: $871M+8.3%
Stock-Based Comp

$3.5M

Previous: $1.42M+146.6%

Revenue & EPS history

Astrana Health · Revenue · Quarterly

$317M

Q3 2022+39.6%vs Q3 2021
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Forward guidance

The Company is raising annual guidance for revenue, net income and EBITDA, and reiterating guidance for Adjusted EBITDA.

Tailwinds

  • Total Revenue: $1,095.0 - $1,115.0 million (previous: $1,055.0 - $1,085.0 million)
  • Net Income: $50.5 - $67.0 million (previous: $38.0 - $57.0 million)
  • EBITDA: $107.5 - $133.5 million (previous: $81.0 - $111.0 million)
  • Adjusted EBITDA: $136.0 - $166.0 million (reiterated)

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.7%

Avg return

Earnings day

-2.1%

Avg return

5 days after

+2.1%

Avg return

30 days after

40%

23 / 57 earnings

Positive

+83.3%

Q3 2011

Best reaction

-40.5%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+29.4%+22.5%+20.6%
Q3 2025-23.4%-29.4%-33.8%
Q1 2025-11.1%-20.8%-24.5%
Q4 2024-26.8%+5.0%+16.1%
Q3 2024-21.1%-27.9%-30.4%
Q2 2024-1.4%-1.8%+0.1%
Q1 2024-0.7%+1.5%+8.0%
Q4 2023+2.3%+1.8%-1.9%
Q3 2023+9.3%+2.9%+13.4%
Q2 2023+4.2%+3.5%-17.4%
Q1 2023+5.4%+7.0%-0.8%
Q4 2022+6.9%+5.2%+15.2%
Q3 2022+8.4%+8.9%-14.5%
Q2 2022-4.3%-11.0%-29.3%
Q1 2022-0.5%-5.4%-26.4%
Q4 2021-2.0%-11.0%-7.0%
Q3 2021+14.7%+30.5%+0.8%
Q2 2021-11.8%-10.7%-12.9%
Q1 2021+4.5%+4.7%+10.9%
Q4 2020+9.1%+8.8%+8.3%
Q3 2020-1.2%-1.6%+0.5%
Q2 2020+1.8%+2.4%+7.9%
Q1 2020-10.4%-11.6%+13.1%
Q4 2019-12.9%-24.0%+7.0%
Q3 2019-2.9%-0.9%+25.0%
Q2 2019-5.0%+4.8%+31.1%
Q1 2019-1.2%-4.3%-29.7%
Q4 2018-6.4%-8.3%-6.9%
Q3 2018+26.3%+4.0%-4.6%
Q2 2018-13.7%-23.3%-32.2%
Q4 2017+10.8%-6.3%+2.1%
Q1 2018+10.8%-6.3%+2.1%
Q3 2017+3.9%+3.9%+140.0%
Q2 2017+0.0%+0.0%-10.5%
Q1 2017+0.0%+6.7%+36.7%
Q1 2016+4.0%+4.0%+0.0%
Q3 2016-4.8%
Q2 2016-12.9%
Q1 2015-6.5%
Q3 2015-3.2%
Q2 2015+0.0%
Q2 2014+15.6%
Q4 2013
Q3 2013+1.6%
Q2 2013+13.5%
Q1 2013-13.3%
Q4 2012-2.2%
Q3 2012-9.1%
Q2 2012-40.5%
Q1 2012+0.0%
Q4 2011
Q3 2011+83.3%
Q2 2011+0.5%
Q1 2011-0.5%
Q4 2010-3.9%
Q3 2010+19.0%
Q2 2010+0.0%
Q1 2010-2.1%
Q4 2009+9.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro